Meeting of the Tick-Borne Disease Working Group, 66714-66715 [2022-23989]

Download as PDF 66714 Federal Register / Vol. 87, No. 213 / Friday, November 4, 2022 / Notices October 19, 2022 SusanH/lftington, -Pt(D. Medical Director The Cleveland Clinic F'oundatio11 9:500 Euclid Avenue Cleveland, OH 44195 Re: Revoi:ation of EUA210363. Deat Dt Hattiftgton: 'llri.s letter is in: ri$ponse to th.e request from Cleveland Clmk RobertJ. TotnSich Path.ology and Laboratory Medicine Irtstttute («Cleveland Clinic:), received via emai1 on October 7, 2022, that the D.S. Food and DrugA:dministra:tion (FDA) revoke the EUAfor the SelfCheck COVJD-l.9 TaqPath Muitiptex PCll assay issued on August~~ 202L Ckweland Clinic indi:eated thatit is no Jo~er osing the SeIICh~k COVIP~19 TaqPath Multiplet PCR.a$say and does not plan to -use it in the future, The authorizatio11 ot a device tor emetgertcy use under section 564 otilie.ltedetal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360bbb;:3) may, pursuant tQ s.ectiQn .564(g)(:2) Qf the Act, be revoked ·when cii:cµmst@ces nrakli} such revocation appropriate to protect the pt1.blic beal:th or sat.ety (section S:64(g)(2)(C) otthe Ac{). Because Cleveland Clinic has notified FDA thatit is.no longerusingtbe Selroheck COVID-19 t'aqPath Multiplex PCR.assa.y and does not plan. to use. it itt the :futute and :requ:ested FDAtevoke the BUA for the SelfCheck COVID•li;> taqPath Mui.tjplex PCR.assay;. FDA has ti'etermined that itis appropriate iQ ptot®I lhe publichealtl:tor safe:ty to rin"Q:ke this authorization. Accordingly, FDA here!:)y revoke~ EUA2103'63 for the Selfeheck COVID-1? TaqPath Multiplex PCR assay, pursuant to section 564($)(2)(C) of the Act. As of the date of this letter, the SelfCheck COVIO- l9TaqPath Multiplex PCR assay is no longer authorized for 6111etgency use by FDA Notice of this revocation will be pqhfished in the FederatRegister; pursuanttQ sectfon 564(h)(1) oftheAct. Isl Nami,tndje N, B!llll.Plli!, Ph.D. Chief Scientist :Food and Drug Administration Secretary, Department of Health and Human Services. ACTION: Notice; revision to meeting date. [FR Doc. 2022–24072 Filed 11–3–22; 8:45 am] khammond on DSKJM1Z7X2PROD with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Tick-Borne Disease Working Group Office of the Assistant Secretary for Health, Office of the AGENCY: VerDate Sep<11>2014 18:12 Nov 03, 2022 The Office of the Assistant Secretary for Health published a notice in the Federal Register on September 16, 2022, concerning a meeting of the Tick-Borne Disease Working Group (TBDWG) that was scheduled to occur on December 7, 2022. This notice is being amended to announce that the meeting has been rescheduled to November 21, 2022. This will be the final TBDWG meeting. SUMMARY: BILLING CODE 4164–01–C Jkt 259001 PO 00000 Frm 00076 Fmt 4703 Sfmt 4703 The meeting date announced in the Federal Register at 87 FR 5693 on September 16, 2022 is amended. The public can view the meeting online via webcast on November 21, 2022 from approximately 10 a.m. to 12 p.m. ET (times are tentative and subject to change). The confirmed times and agenda items for the meeting will be posted on the TBDWG web page at https://www.hhs.gov/ash/advisorycommittees/tickbornedisease/meetings/ index.html when this information becomes available. DATES: E:\FR\FM\04NON1.SGM 04NON1 EN04NO22.075</GPH> Dated: October 31, 2022. Lauren K. Roth, Associate Commissioner for Policy. Federal Register / Vol. 87, No. 213 / Friday, November 4, 2022 / Notices FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal Officer for the TBDWG; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Tower Building, 1101 Wootton Parkway, Rockville, MD 20852. Email: tickbornedisease@hhs.gov. Phone: 202– 795–7608. A link to view the webcast can be found on the meeting website at https://www.hhs.gov/ ash/advisory-committees/ tickbornedisease/meetings/ when it becomes available. The public will have an opportunity to present their views to the TBDWG orally during the meeting’s public comment session or by submitting a written public comment. Comments should be pertinent to the meeting discussion. Persons who wish to provide verbal or written public comment should review instructions at https://www.hhs.gov/ ash/advisory-committees/ tickbornedisease/meetings/ and respond by midnight November 13, 2022 ET. Verbal comments will be limited to three minutes each to accommodate as many speakers as possible during the 30-minute session. Written public comments will be accessible to the public on the TBDWG web page prior to the meeting. SUPPLEMENTARY INFORMATION: Dated: October 25, 2022. James J. Berger, Designated Federal Officer, Tick-Borne Disease Working Group, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2022–23989 Filed 11–3–22; 8:45 am] would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) Re-Issue PA– 20–207. Date: December 5–7, 2022. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G13B, Rockville, MD 20892 (Virtual Meeting). Contact Person: Yong Gao, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G13B, Rockville, MD 20852, (240) 669–5048, yong.gao@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS). Dated: November 1, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–24064 Filed 11–3–22; 8:45 am] National Institutes of Health khammond on DSKJM1Z7X2PROD with NOTICES National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which VerDate Sep<11>2014 18:12 Nov 03, 2022 Jkt 259001 Dated: November 1, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–24063 Filed 11–3–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Toxicology Program Board of Scientific Counselors; Announcement of Meeting; Request for Comments National Institutes of Health, HHS. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting BILLING CODE 4150–28–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22B, Rockville, MD 20892 (Virtual Meeting). Contact Person: Kristina S. Wickham, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22B, Rockville, MD 20852, 301–761–5390, kristina.wickham@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) AGENCY: BILLING CODE 4140–01–P 66715 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed). Date: November 30–December 1, 2022. Time: 10:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 ACTION: Notice. This notice announces the next meeting of the National Toxicology Program (NTP) Board of Scientific Counselors (BSC). The BSC, a federally chartered, external advisory group composed of scientists from the public and private sectors, will review and provide advice on programmatic activities. This meeting is a virtual meeting and is open to the public. Written comments will be accepted, and registration is required to present oral comments. DATES: Meeting: Scheduled for December 15, 2022, 1:30 p.m.–5:00 p.m. Eastern Standard Time (EST). Ending times are approximate; meeting may end earlier or run later. Written Public Comment Submissions: Deadline is December 08, 2022. Registration for Oral Comments: Deadline is December 08, 2022. ADDRESSES: Meeting web page: The preliminary agenda, registration, and other meeting materials will be available at https://ntp.niehs.nih.gov/go/165 by November 10, 2022. Virtual Meeting: The URL for viewing the virtual meeting will be provided on the meeting web page the day before the meeting. FOR FURTHER INFORMATION CONTACT: Dr. Milene Brownlow, Designated Federal SUMMARY: E:\FR\FM\04NON1.SGM 04NON1

Agencies

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 87, Number 213 (Friday, November 4, 2022)]
[Notices]
[Pages 66714-66715]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23989]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Tick-Borne Disease Working Group

AGENCY: Office of the Assistant Secretary for Health, Office of the 
Secretary, Department of Health and Human Services.

ACTION: Notice; revision to meeting date.

-----------------------------------------------------------------------

SUMMARY: The Office of the Assistant Secretary for Health published a 
notice in the Federal Register on September 16, 2022, concerning a 
meeting of the Tick-Borne Disease Working Group (TBDWG) that was 
scheduled to occur on December 7, 2022. This notice is being amended to 
announce that the meeting has been rescheduled to November 21, 2022. 
This will be the final TBDWG meeting.

DATES: The meeting date announced in the Federal Register at 87 FR 5693 
on September 16, 2022 is amended. The public can view the meeting 
online via webcast on November 21, 2022 from approximately 10 a.m. to 
12 p.m. ET (times are tentative and subject to change). The confirmed 
times and agenda items for the meeting will be posted on the TBDWG web 
page at https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/ when this information becomes available.

[[Page 66715]]


FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal 
Officer for the TBDWG; Office of Infectious Disease and HIV/AIDS 
Policy, Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Tower Building, 1101 Wootton Parkway, 
Rockville, MD 20852. Email: [email protected]. Phone: 202-795-
7608.

SUPPLEMENTARY INFORMATION: A link to view the webcast can be found on 
the meeting website at https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/ when it becomes available. The 
public will have an opportunity to present their views to the TBDWG 
orally during the meeting's public comment session or by submitting a 
written public comment. Comments should be pertinent to the meeting 
discussion. Persons who wish to provide verbal or written public 
comment should review instructions at https://www.hhs.gov/ash/advisory-committees/tickbornedisease/meetings/ and respond by midnight 
November 13, 2022 ET. Verbal comments will be limited to three minutes 
each to accommodate as many speakers as possible during the 30-minute 
session. Written public comments will be accessible to the public on 
the TBDWG web page prior to the meeting.

    Dated: October 25, 2022.
James J. Berger,
Designated Federal Officer, Tick-Borne Disease Working Group, Office of 
Infectious Disease and HIV/AIDS Policy.
[FR Doc. 2022-23989 Filed 11-3-22; 8:45 am]
BILLING CODE 4150-28-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.